Aggarwal R, et al. - In an open-label clinical trial, repository corticotropin injection (RCI) was tested with respect to its efficacy, safety, tolerability and steroid-sparing effect in refractory adult polymyositis (PM) and dermatomyositis (DM). In patients with adult myositis refractory to glucocorticoid and traditional immunosuppressive drugs, RCI was proved to be a safe and tolerable treatment option, with reported efficacy in 70% of patients. Moreover, it caused steroid dose reduction as well in this patient population.